Belite Bio CEO Lin Yu-Hsin sells $19.08m in company shares

Belite Bio's Chief Executive Officer, Lin Yu-Hsin, divested a significant portion of the company's shares, amounting to about $19.08 million, in a series of transactions conducted on September 4 and September 8, 2026. The shares were traded at prices fluctuating between $180.00 and $198.37, close to the stock's 52-week peak of $200.

This sale of 90,835 American depositary shares, each representing a single ordinary share, coincided with BELITE BIO's impressive 176% increase in value over the past year. The transactions were executed under a pre-approved Rule 10b5-1 trading plan adopted by Lin on December 23, 2025. Following these sales, Lin retained a beneficial ownership of 70,134 American depositary shares.

In related news, BELITE BIO has achieved notable progress with its drug tinlarebant, designed to treat Stargardt disease type 1. The company recently submitted a New Drug Application to Japan's Ministry of Health, Labour, and Welfare, receiving Sakigake Designation for expedited review. Financial analysts have shown strong confidence in BELITE BIO, with H.C.

Wainwright raising its price target to $245 and Mizuho increasing its target to $234, both maintaining a Buy rating. Canaccord Genuity initiated coverage with a Buy rating and a $303 target, citing optimism about tinlarebant's potential to mitigate vision loss. The FDA has also accepted BELITE BIO's New Drug Application for tinlarebant, granting it Priority Review with a PDUFA target date of February 12, 2027.

These developments highlight the company's growing commercial prospects, with Benchmark maintaining a Buy rating and a $217 price target, and H.C. Wainwright reaffirming a Buy rating with a $214 target.